Freegold Ventures Limited Announces $30 Million Brokered Private Placement Financing
Freegold Cashes Up for PFS as Massive Alaska Resource De-Risks via Metallurgical Breakthroughs
Freegold Ventures (FVL) has announced a $30 million brokered private placement at $1.30 per share with no warrants, utilizing the Listed Issuer Financing Exemption. This follows a string of positive technical updates, most notably the December 16, 2025, report detailing a 98% arsenic reduction and a 47% gold concentrate grade increase (to 24.7 g/t Au) using the GlassLock Process™. These metallurgical results complement a July 2025 Mineral Resource Estimate (MRE) that significantly expanded the Golden Summit project to 17.2 million ounces (Moz) Indicated (1.24 g/t Au) and 11.9 Moz Inferred (1.04 g/t Au).
The impact is Material - Positive for three specific reasons: - Financial De-risking: The $30M raise, following a $42M raise in April 2025, provides the necessary treasury to complete the Pre-Feasibility Study (PFS) and 2026 exploration without immediate insolvency risk. - Cost of Capital Improvement: The Dec 2025 financing is priced at $1.30 per share with no warrants. This is a significant improvement over the April 2025 financing at $0.85 with half-warrants, indicating increasing institutional/market confidence and less future dilution. - Technical Validation: The metallurgical results (90-95% recoveries via oxidation) address the primary "fatal flaw" risk of the Golden Summit project—its refractory nature. Previously, recoveries were estimated at only 72%. Moving toward 90%+ recoveries fundamentally changes the project's potential NPV.
Freegold Ventures' flagship is the Golden Summit Project, located near Fairbanks, Alaska. It is situated near the Fort Knox mine, providing excellent infrastructure access. The project has grown into one of North America's largest undeveloped gold deposits. - Stage: Moving from Resource Expansion to Pre-Feasibility (PFS). - Scale: 17.2 Moz Indicated and 11.9 Moz Inferred. - Metallurgy: Refractory ore requires oxidation (POX, BIOX, or Albion), but recent tests show >90% recovery is achievable.